Jade Biosciences, Inc. JBIO
Jade Biosciences, Inc. (Nasdaq: JBIO) is an immunology/inflammation drug developer. Its lead program, JADE101, is in Phase 2 for IgA nephropathy (IgAN). Its next catalyst on record is JADE101: Initiate registrational Phase 3 in IgAN (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: JADE101 — Initiate registrational Phase 3 in IgAN (H1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| JADE101 (anti-APRIL mAb) | IgA nephropathy; JUNIPER open-label Phase 2 (~30 patients) dosing since May 2026 | antibody | Phase 2 |
| JADE201 (anti-BAFF-R mAb) | multiple autoimmune disorders (initially rheumatoid arthritis) | antibody | Pre-clinical |
| JADE301 (anti-IFN-beta mAb) | dermatomyositis | antibody | Pre-clinical |
Recent results and decisions
- Jun 1, 2026positive Interim Phase 1 SAD in 32 healthy volunteers: well tolerated with no SAEs or severe TEAEs; ~70% IgA reduction after single dose, >90% APRIL suppression sustained median 85 days at 700 mg.
Prolonged IgA reductions of ~70% following a single dose of JADE101
Filing - Jun 1, 2026started Phase 2 randomized open-label IgAN patient trial initiated (700 mg induction then 350 mg Q12W or Q8W); interim data 2027.
JADE101 Phase 2 IgAN patient trial initiated; interim data anticipated in 2027
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.